Efficacy of TNF   blockade in cyclophosphamide resistant neuro-Behcet disease

Ribi, Camillo

doi:10.1136/jnnp.2004.055434

Cited by 63 publications

(25 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Successful treatment of neurologic manifestations of BS with monoclonal anti-TNF alpha antibody treatment with infliximab in a few patients has been reported recently [15,43,54,73,81]. However, the occurrence of neuro-relapses after stopping infliximab, formation of neutralizing antibodies and the probability of increased CNS auto-immunity with monoclonal anti-TNF alpha antibody treatment [74] should be also kept in mind.…”

Section: Treatmentmentioning

confidence: 97%

The spectrum of nervous system involvement in Behçet’s syndrome and its differential diagnosis

2009

View full text Add to dashboard Cite

Behçet's Syndrome (BS) is a multi-system, vascular-inflammatory disease of unknown origin, involving the nervous system in a subgroup of patients. The growing clinical and imaging evidence suggests that primary neurological involvement in BS may be subclassified into two major forms: the first one, which is seen in the majority of patients, may be characterized as a vascular-inflammatory central nervous system (CNS) disease, with focal or multifocal parenchymal involvement mostly presenting with a subacute brainstem syndrome and hemiparesis; the other, which has few symptoms and a better neurological prognosis, may be caused by isolated cerebral venous sinus thrombosis and intracranial hypertension. These two types rarely occur in the same individual, and their pathogenesis is likely to be different. Isolated behavioral syndromes and peripheral nervous system involvement are rare, whereas a nonstructural vascular type headache is relatively common and independent from neurological involvement. Neurologic complications secondary to systemic involvement of BS such as cerebral emboli from cardiac complications of BS and increased intracranial pressure due to superior vena cava syndrome, as well as neurologic complications related to BS treatments such as CNS neurotoxicity with cyclosporine and peripheral neuropathy with the use of thalidomide or colchisin are considered as secondary neurological complications of this syndrome. As the neurological involvement in this syndrome is so heterogeneous, it is difficult to predict its course and prognosis, and response to treatment. Currently, treatment options are limited to attack and symptomatic therapies with no evidence for the efficacy of any long term preventive treatment.

show abstract

Section: Treatmentmentioning

confidence: 97%

The spectrum of nervous system involvement in Behçet’s syndrome and its differential diagnosis

2009

View full text Add to dashboard Cite

show abstract

“…This fact, in addition to the severe course in the reported Albanian patients, could indicate that ABD is still 'unknown' in the country or that less severe cases could be misdiagnosed. Further, neuro-ABD is a rarely diagnosed manifestation but it could be underestimated, if cerebral radiological imaging is [3,24,25,45] . Last, this case emphasizes the unpredictability of ABD even with combined immunosuppression (development of an ocular involvement despite therapy) and corroborates the evidence of efficacy and a favourable safety profile of TNF-␣ inhibitors in the treatment of ABD refractory to conventional immunosuppressive drugs, as already reported by other authors.…”

Section: Case Reportmentioning

confidence: 99%

Infliximab for the Treatment of Refractory Adamantiades-Behçet Disease with Articular, Intestinal, Cerebral and Ocular Involvement

Donghi¹,

Mainetti²

2010

Dermatology

View full text Add to dashboard Cite

“…Infliximab was also administered in patients with neuro-Behçet refractory to high doses of steroids combined with cyclosporine, azathioprine, or MTX Licata et al 2003;Ribi et al 2005;Sarwar et al 2005;Fujikawa et al 2007;Kikuchi et al 2008;Pipitone et al 2008;AbalosMedina et al 2009]. The infliximab dose most commonly used was 3-5 mg/kg administered at 0, 2, and 6 weeks and every 6-8 weeks.…”

mentioning

confidence: 99%

Update on the therapy of Behçet disease

Saleh

Arayssi

2014

Therapeutic Advances in Chronic Disease

116

101

View full text Add to dashboard Cite

Behçet disease is a chronic inflammatory systemic disorder, characterized by a relapsing and remitting course. It manifests with oral and genital ulcerations, skin lesions, uveitis, and vascular, central nervous system and gastrointestinal involvement. The main histopathological finding is a widespread vasculitis of the arteries and veins of any size. The cause of this disease is presumed to be multifactorial involving infectious triggers, genetic predisposition, and dysregulation of the immune system. As the clinical expression of Behçet disease is heterogeneous, pharmacological therapy is variable and depends largely on the severity of the disease and organ involvement. Treatment of Behçet disease continues to be based largely on anecdotal case reports, case series, and a few randomized clinical trials.

show abstract

Efficacy of TNF blockade in cyclophosphamide resistant neuro-Behcet disease

Cited by 63 publications

References 10 publications

The spectrum of nervous system involvement in Behçet’s syndrome and its differential diagnosis

The spectrum of nervous system involvement in Behçet’s syndrome and its differential diagnosis

Infliximab for the Treatment of Refractory Adamantiades-Behçet Disease with Articular, Intestinal, Cerebral and Ocular Involvement

Update on the therapy of Behçet disease

Contact Info

Product

Resources

About